CN106604916A - 钾离子竞争性酸阻滞剂的晶型及其制备方法 - Google Patents

钾离子竞争性酸阻滞剂的晶型及其制备方法 Download PDF

Info

Publication number
CN106604916A
CN106604916A CN201580047199.6A CN201580047199A CN106604916A CN 106604916 A CN106604916 A CN 106604916A CN 201580047199 A CN201580047199 A CN 201580047199A CN 106604916 A CN106604916 A CN 106604916A
Authority
CN
China
Prior art keywords
crystalline form
solvent
solution
precipitate
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201580047199.6A
Other languages
English (en)
Other versions
CN106604916B (zh
Inventor
唐红伟
孙长安
王瑞军
袁恒立
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Original Assignee
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hansoh Pharmaceutical Group Co Ltd filed Critical Jiangsu Hansoh Pharmaceutical Group Co Ltd
Publication of CN106604916A publication Critical patent/CN106604916A/zh
Application granted granted Critical
Publication of CN106604916B publication Critical patent/CN106604916B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及钾离子竞争性酸阻滞剂即1‑[5‑(2‑氟苯基)‑1‑(吡啶‑3‑基磺酰基)‑1H‑吡咯‑3‑基]‑N‑甲基甲胺富马酸盐(以下简称式I)的晶型及其制备方法，其X射线粉末衍射特征峰如附图1所示。本发明所提供的式I晶型性状稳定，可重复性好，适合药物开发。

Description

PCT国内申请，说明书已公开。

Claims (14)

  1. PCT国内申请，权利要求书已公开。
CN201580047199.6A 2014-11-12 2015-11-09 钾离子竞争性酸阻滞剂的晶型及其制备方法 Active CN106604916B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410637759.0A CN105646451A (zh) 2014-11-12 2014-11-12 钾离子竞争性酸阻滞剂的晶型及其制备方法
CN2014106377590 2014-11-12
PCT/CN2015/094120 WO2016074597A1 (zh) 2014-11-12 2015-11-09 钾离子竞争性酸阻滞剂的晶型及其制备方法

Publications (2)

Publication Number Publication Date
CN106604916A true CN106604916A (zh) 2017-04-26
CN106604916B CN106604916B (zh) 2020-03-03

Family

ID=55953739

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201410637759.0A Pending CN105646451A (zh) 2014-11-12 2014-11-12 钾离子竞争性酸阻滞剂的晶型及其制备方法
CN201580047199.6A Active CN106604916B (zh) 2014-11-12 2015-11-09 钾离子竞争性酸阻滞剂的晶型及其制备方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201410637759.0A Pending CN105646451A (zh) 2014-11-12 2014-11-12 钾离子竞争性酸阻滞剂的晶型及其制备方法

Country Status (5)

Country Link
US (1) US10538506B2 (zh)
EP (1) EP3219710B1 (zh)
CN (2) CN105646451A (zh)
TW (1) TWI702211B (zh)
WO (1) WO2016074597A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9898175B2 (en) 2014-08-05 2018-02-20 Fibar Group S.A. Home network manager for home automation
CN105315258A (zh) * 2015-05-16 2016-02-10 南京海纳医药科技有限公司 富马酸沃诺拉赞多晶型及其制备方法
US10912769B2 (en) 2016-09-29 2021-02-09 Jiangsu Jibeier Pharmaceutical Co. Ltd. 1-[(pyridin-3-yl-sulfonyl)-1H-pyrrol-3-yl] methanamine derivative and pharmaceutical composition and use thereof
CN113620930B (zh) * 2021-07-12 2022-08-16 南京烁慧医药科技有限公司 一种含磺酰胺结构的化合物及其制备方法和应用、一种药物组合物及应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1803709A1 (en) * 2004-09-30 2007-07-04 Takeda Pharmaceutical Company Limited Proton pump inhibitors
CN101300229A (zh) * 2005-08-30 2008-11-05 武田药品工业株式会社 作为胃酸分泌抑制剂的1-杂环基磺酰基、2-氨基甲基、5-(杂)芳基取代的1-h-吡咯衍生物
WO2014133059A1 (ja) * 2013-02-28 2014-09-04 武田薬品工業株式会社 スルホニルクロライド化合物の製造法
CN104327051A (zh) * 2014-10-13 2015-02-04 成都盛迪医药有限公司 一种吡咯衍生物的富马酸盐的结晶形式

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1803709A1 (en) * 2004-09-30 2007-07-04 Takeda Pharmaceutical Company Limited Proton pump inhibitors
CN101300229A (zh) * 2005-08-30 2008-11-05 武田药品工业株式会社 作为胃酸分泌抑制剂的1-杂环基磺酰基、2-氨基甲基、5-(杂)芳基取代的1-h-吡咯衍生物
WO2014133059A1 (ja) * 2013-02-28 2014-09-04 武田薬品工業株式会社 スルホニルクロライド化合物の製造法
CN104327051A (zh) * 2014-10-13 2015-02-04 成都盛迪医药有限公司 一种吡咯衍生物的富马酸盐的结晶形式

Also Published As

Publication number Publication date
WO2016074597A1 (zh) 2016-05-19
EP3219710A4 (en) 2018-05-09
US10538506B2 (en) 2020-01-21
TWI702211B (zh) 2020-08-21
TW201617336A (zh) 2016-05-16
CN106604916B (zh) 2020-03-03
EP3219710B1 (en) 2020-08-26
EP3219710A1 (en) 2017-09-20
US20180282300A1 (en) 2018-10-04
CN105646451A (zh) 2016-06-08

Similar Documents

Publication Publication Date Title
CN106604916B (zh) 钾离子竞争性酸阻滞剂的晶型及其制备方法
DK3045175T3 (en) POLYMORPHE FORMS OF 3- (4-AMINO-1-OXO-1,3-DIHYDROISOINDOL-2-YL) -PIPERIDIN-2,6-DION
SK172999A3 (en) Omeprazole sodium salt
US20040010151A1 (en) Lansoprazole polymorphs and processes for preparation thereof
WO2010129636A2 (en) Lenalidomide polymorph
CN115385845B (zh) 一种吡咯磺酸类化合物盐型制备
US10206916B2 (en) Cabozantinib salts and their use as anti-cancer agents
JP2008545768A (ja) オメプラゾールナトリウムの結晶性溶媒和物
JP2017534655A (ja) Ａｘｌチロシン受容体キナーゼ阻害剤「Ｒ４２８」の精製方法
KR102528854B1 (ko) 메사코닌의 결정형 및 그의 제조방법
EP1765807B1 (en) Solid forms of the magnesium salt of (s)-omeprazole and processes for their preparation
WO2014195977A2 (en) Novel polymorphs of vismodegib
US20220153718A1 (en) Synthesis of stable amorphous apalutamide
TWI680983B (zh) 一種鈉－葡萄糖共同轉運蛋白２抑制劑的ｌ－脯胺酸複合物、其一水合物及晶體
EP3272734A1 (en) Ahu377 crystal form, preparation method and use thereof
EP3002286A1 (en) Preparation method for polymorphic 6-(4-chlorophenoxy)-tetrazolo[5,1-a]phthalazine and use thereof
CN107778289B (zh) 5-(2-氟苯基)-n-甲基-1-(3-吡啶基磺酰基)-1h-吡咯-3-甲氨醋酸盐的多晶型物
CN108473506A (zh) 噻吩并嘧啶化合物的盐酸盐的结晶形式
EP2824104A1 (en) Process for the preparation of form III of Vilazodone hydrochloride
JP2010215507A (ja) ２−［［４−（３−メトシキプロポキシ）−３−メチルピリジン−２−イル］メチルスルフィニル］−１ｈ−ベンズイミダゾールナトリウムの結晶及びその製造方法
CN114075186A (zh) 化合物x7盐酸盐的晶体及其制备方法与应用
TW202434246A (zh) Alk抑制劑或其鹽、溶劑合物的結晶形式及其製備方法和應用
EP3293174A1 (en) Crystalline salts of betrixaban
WO2017037743A2 (en) Dabigatran etexilate 1,4-butanedisulfonate salt and its crystal form
EP2154137A1 (en) Crystalline form of moxifloxacin base

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant